LiraglutideGLP-1 receptor agonist
Liraglutide is a GLP-1 receptor agonist used in medicines for type 2 diabetes and weight management. The same molecule can appear in products with different treatment goals and dosing programmes.
What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist used in different products for type 2 diabetes and weight management. The active ingredient is shared, but products such as Victoza and Saxenda have distinct treatment purposes. 1
How it works
GLP-1 receptor activation affects glucose-dependent insulin release, glucagon, appetite and gastric emptying. These actions connect blood-glucose control with changes in food intake. 1
Effects studied
Type 2 diabetes glucose control
Studied and used to improve glucose regulation in defined diabetes treatment settings.
Evidence: Product-specific clinical evidence. 1
Cardiovascular outcomes
LEADER studied cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk. Its findings do not establish a longevity benefit in healthy people.
Evidence: Randomised cardiovascular outcomes trial. 4
What does the evidence show?
The archive includes product information and the LEADER cardiovascular trial. A benefit observed in a high-risk diabetes population cannot automatically be applied to healthy people.
How it changes metabolic signalling
GLP-1 receptor activation influences insulin and glucagon responses, appetite and gastric emptying. Liraglutide is modified to last longer than the natural hormone. These linked mechanisms help explain its clinical uses, but they also explain why gastrointestinal symptoms and other effects need monitoring.
One molecule, different product questions
Victoza and Saxenda are used in different treatment programmes. Although both contain liraglutide, their instructions are not interchangeable. Each product needs to be assessed against its indication, formulation and local prescribing information.
What the cardiovascular trial does and does not show
LEADER studied people with type 2 diabetes and elevated cardiovascular risk. Its cardiovascular findings belong to that setting. They should not become a broad claim that liraglutide improves longevity for anyone seeking weight loss, and they do not remove the need to assess individual eligibility. 4
The benefit comes with a tolerability question
Nausea, vomiting and diarrhoea can make treatment difficult to tolerate. Gallbladder problems, pancreatitis concerns and dehydration also need attention. Product warnings differ by jurisdiction and require a current check. Weight loss is one part of the assessment, alongside these risks and the burden of treatment. 1
Safety & status
Nausea, vomiting and diarrhoea can affect treatment. Gallbladder problems, pancreatitis concerns and dehydration also require attention to the relevant product information. 1
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Are its diabetes and weight-management products the same treatment?
They contain the same active molecule but have different indications and instructions. One product’s label should not be substituted for another.
Does LEADER tell us about healthy people taking it for longevity?
No. The trial population had type 2 diabetes and high cardiovascular risk. 4
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Liraglutide: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Liraglutide: www.drugs.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Liraglutide: www.sciencedirect.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
- Liraglutide: paper 10.1056/NEJMoa1603827 Research reference · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.